F-1: Altamira Therapeutics Announces Proposed Public Offering of Common Shares and Warrants

Altamira Therapeutics is planning a public offering of common shares, pre-funded warrants, and accompanying warrants to raise capital for working capital and general corporate purposes.

Summary

• Altamira Therapeutics Ltd. has filed a registration statement for a proposed public offering.
• The offering includes common shares, pre-funded warrants to purchase common shares, Series A-1 warrants, Series A-2 warrants, placement agent warrants, and common shares underlying these warrants.
• The company intends to use the net proceeds from this offering for working capital and general corporate purposes.
• The offering is being conducted on a reasonable best efforts basis with no minimum amount of securities required to be sold.
• The assumed combined public offering price is $ per common share and accompanying common warrants, based on the closing price on August 21, 2024.
• The company has engaged a placement agent to assist with the offering and will pay fees and warrants as compensation.
• The offering is expected to be completed on or about , 2024, subject to customary closing conditions.
• The company's common shares are listed on Nasdaq under the symbol CYTO.
• The company is a foreign private issuer and is subject to reduced public company reporting requirements.

Sentiment

Score: 4

Explanation: The document is primarily factual and descriptive, but the mention of going concern issues and potential dilution weighs negatively on the sentiment.

Positives

• The offering will provide Altamira Therapeutics with additional capital for working capital and general corporate purposes.
• The company has a versatile RNA delivery platform that is also suited for mRNA and other RNA modalities and made available to pharma or biotech companies through out-licensing.
• The company has announced the publication of a peer-reviewed article in Nature Immunology demonstrating a significant reduction in tumor growth in animal cancer models through treatment with Zbtb46 mRNA delivered with Altamiras SemaPhore nanoparticle technology.
• The company has announced the preprint publication of a study demonstrating effective treatment of abdominal aortic aneurysm (AAA) in an animal model.

Negatives

• The offering is being conducted on a reasonable best efforts basis, and there is no guarantee that the company will raise the amount of capital it needs.
• Investors will experience immediate and substantial dilution in the net tangible book value of their common shares.
• There is no public market for the pre-funded warrants or the common warrants being sold in this offering.
• The company has broad discretion in how it uses the net proceeds of this offering.
• The company needs to raise capital in this offering to support its operations, and there is substantial doubt about its ability to continue as a going concern.

Risks

• Purchasers who purchase our Securities in this offering pursuant to a securities purchase agreement may have rights not available to purchasers that purchase without the benefit of a securities purchase agreement.
• The Placement Agent has agreed to use its reasonable best efforts to solicit offers to purchase the Securities in this offering.
• We may sell fewer than all of the Securities offered hereby, which may significantly reduce the amount of proceeds received by us, and investors in this offering will not receive a refund in the event that we do not sell an amount of Securities sufficient to support our business goals and continued operations, including our near-term continued operations.
• If you purchase our Securities in this offering, you will incur immediate and substantial dilution in the net tangible book value of your Common Shares.
• There is no public market for the Pre-Funded Warrants or the Common Warrants sold in this offering.
• We need to raise capital in this offering to support our operations, and there is substantial doubt about our ability to continue as a going concern.
• Our Common Shares may be involuntarily delisted from trading on The Nasdaq Capital Market if we fail to comply with the continued listing requirements.
• If we are or become classified as a passive foreign investment company (PFIC), our U.S. shareholders and holders of the Common Warrants and Pre-Funded Warrant may suffer adverse tax consequences as a result.

Future Outlook

The company intends to use the net proceeds from this offering for working capital and other general corporate purposes.

Industry Context

The company is operating in the biopharmaceutical industry, which is characterized by high risk and uncertainty. The success of the company's product candidates depends on a number of factors, including the results of clinical trials, regulatory approvals, and market acceptance.

Stakeholder Impact

• Shareholders will experience dilution as a result of the offering.
• The company's employees will benefit from the additional capital, which will allow the company to continue to develop its product candidates.
• Customers may benefit from the company's product candidates if they are approved and commercialized.
• Suppliers will benefit from the company's increased spending on research and development.
• Creditors may be at risk if the company is unable to raise sufficient capital to continue as a going concern.

Next Steps

• The company will continue to develop its RNA delivery platforms and product candidates.
• The company will seek regulatory approvals for its product candidates.
• The company will commercialize its product candidates.
• The offering is expected to be completed on or about , 2024, subject to satisfaction of customary closing conditions.

Key Dates

Keywords

public offering, common shares, warrants, pre-funded warrants, placement agent, RNA delivery, capital raise, CYTO, Altamira Therapeutics, securities